BOC Sciences Diversifies Immune Checkpoint Inhibitors and Nonspecific Immune Stimulation for Cancer Immunotherapy

Headquartered in Shirley, New York, the world’s reputed chemical supplier BOC Sciences announced to diversify its immune checkpoint inhibitors as well as nonspecific immune stimulation targets for scientific research targeting cancer immunotherapy (https://www.bocsci.com/tag/cancer-immunotherapy-36.html) on August 29, 2018.
Traditionally, surgery, chemotherapy and radiotherapy are the most widely chosen therapies in cancer treatment. However, in recent years, immunotherapy has attracted increasing attention among the research community. Immunotherapy agents do not directly attack the tumor cells but instead mobilize the immune system to do so. This is a major difference and its biggest advantage since it spares the limitations of traditional methods such as severe systemic toxicities and bystander effects on normal cells.
“In the past 100 years, the potential of the immune system to be mobilized to provide a reproducible benefit for patients with cancer has been gradually explored. With the approval of ipilimumab in 2011 by regulatory agencies, the field of cancer immunotherapy comes to the renaissance stage,” revealed Mr. Barron Jones, the Marketing Executive of BOC Sciences, in a statement. “So far, immunotherapy has become a more preferred choice for treating various types of cancer considering its unique potential for substantial and long-term clinical benefit.”
Previously BOC sciences has already had a quite comprehensive collection of immune checkpoint inhibitors and nonspecific immune stimulation targets, but given the importance of immunotherapy, more has been added in the hope of facilitating the research efforts of scientists in this field. Both nonspecific immune stimulation and Immune checkpoint inhibitors belong to the non-antigen-specific strategies of immunotherapy, whereas the antigen-specific strategies generally include adoptive cell transfer of autologous cancer-specific T cells and various therapeutic vaccination approaches.
Examples of immune checkpoint proteins (targets) found on T cells or cancer cells:
• IDO• TDO• PD-1• PD-L1• CTLA4• KIR• 4-1BB(also known as CD137)• OX40 (also known as CD134)• LAG3• B7‑H3(also known as CD276)• TIM3• TIGIT• BTLA• VISTA• ICOS• CD39• CD27• CD30(also known as TNFRSF8)• CD28• B7-H4(also known as B7‑S1, B7x and VCTN1)• HHLA2• Galectins• CD155
Examples of nonspecific immune stimulation proteins (targets) found on T cells or cancer cells:
• TLR• CD40• GITR• CCR• CXCR• Cytokine Receptor• STING• Cox-2• Adenosine A2a• Adenosine A2b• Others (Nonspecific immune stimulation)

About BOC Sciences
Committed to the pharmaceutical industry, BOC Sciences offers a range of high quality APIs, inhibitors, impurities, metabolites, ADCs and other chemicals as needed by researchers. To keep up with the ever-changing world, BOC Sciences also keeps an eye on the trends and efforts in seeking new treatment for major disease like cancer. In the last two decades and more, more platforms such as Virtual Screening (https://www.bocsci.com/virtual-screening.html ) and Screening Libraries (https://www.bocsci.com/screening-libraries-list-7.html ) are added in the hope of facilitating researchers’ efforts as well as accelerating drug R&D process.

BOC Sciences

45-16 Ramsey Road, Shirley, NY 11967, USA

Linna Green

account@bocsci.com

This release was published on openPR.